Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state

Molecular and Cellular Biology

Volumn 26, Issue 17, 2006, Pages 6381-6394

  Kurzer, Jason H ^a   Saharinen, Pipsa ^b   Silvennoinen, Olli ^c   Carter Su, Christin ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; AMINO ACID; CYTOKINE RECEPTOR; JANUS KINASE; JANUS KINASE 2; JANUS KINASE INHIBITOR; MUTANT PROTEIN; PHOSPHOTYROSINE; PROTEIN APS; PROTEIN JH1; PROTEIN JH2; PROTEIN SH2; PROTEIN SH2 B; PROTEIN SH2 BBETA; PROTEIN SUBUNIT; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; GENE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FAMILY; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; DNA, COMPLEMENTARY; ENZYME ACTIVATION; HUMANS; JANUS KINASE 2; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; REGULATORY SEQUENCES, NUCLEIC ACID;

EID: 33747748126     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00570-06     Document Type: Article

References (54)

1. Brown, R. J., J. J. Adams, R. A. Pelekanos, Y. Wan, W. J. McKinstry, K. Palethorpe, R. M. Seeber, T. A. Monks, K. A. Eidne, M. W. Parker, and M. J. Waters. 2005. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12:814-821.
2. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
3. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
4. Dhe-Paganon, S., E. D. Werner, M. Nishi, L. Hansen, Y. I. Chi, and S. E. Shoelson. 2004. A phenylalanine zipper mediates APS dimerization. Nat. Struct. Mol. Biol. 11:968-974.
5. Duan, C., H. Yang, M. F. White, and L. Rui. 2004. Disruption of SH2-B causes age-dependent insulin resistance and glucose intolerance. Mol. Cell. Biol. 24:743507443.
6. Feng, J., B. A. Witthuhn, T. Matsuda, F. Kohlhuber, I. M. Kerr, and J. N. Ihle. 1997. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:2497-2501.
7. Frank, S. J., G. Gilliland, A. S. Kraft, and C. S. Arnold. 1994. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 135:2228-2239.
8. Frank, S. J., W. Yi, Y. Zhao, J. F. Goldsmith, G. Gilliland, J. Jiang, I. Sakai, and A. S. Kraft. 1995. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. J. Biol. Chem. 270:14776-14785.
9. Higgins, D. G., J. D. Thompson, and T. J. Gibson. 1996. Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 266:383-402.
10. Hu, J., J. Liu, R. Ghirlando, A. R. Saltiel, and S. R. Hubbard. 2003. Structural basis for recruitment of the adapter protein APS to the activated insulin receptor. Mol. Cell 12:1379-1389.
11. Huang, X., Y. Li, K. Tanaka, K. G. Moore, and J. I. Hayashi. 1995. Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C γ 1, Grb2, and phosphatidyl-inositol 3-kinase. Proc. Natl. Acad. Sci. USA 92:11618-11622.
12. Iseki, M., S. Takaki, and K. Takatsu. 2000. Molecular cloning of the mouse APS as a member of the Lnk family adaptor proteins. Biochem. Biophys. Res. Commun. 272:45-54.
13. Kotani, K., P. Wilden, and T. S. Pillay. 1998. SH2-Bα is an insulin-receptor adapter protein and substrate that interacts with the activation loop of the insulin-receptor kinase. Biochem. J. 335:103-109.
14. Kralovics, R., F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola, and R. C. Skoda. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779-1790.
15. Kurzer, J. H., L. S. Argetsinger, Y.-J. Zhou, J.-L. Kouadio, J. J. O'Shea, and C. Carter-Su. 2004. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bβ. Mol. Cell. Biol. 24:4557-4570.
16. Lacronique, V., A. Boureux, V. D. Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-1312.
17. Leonard, W. J., and J. J. O'Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322.
18. Levine, R. L., M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig, B. J. Huntly, T. J. Boggon, I. Wlodarska, J. J. Clark, S. Moore, J. Adelsperger, S. Koo, J. C. Lee, S. Gabriel, T. Mercher, A. D'Andrea, S. Frohling, K. Dohner, P. Marynen, P. Vandenberghe, R. A. Mesa, A. Tefferi, J. D. Griffin, M. J. Eck, W. R. Sellers, M. Meyerson, T. R. Golub, S. J. Lee, and D. G. Gilliland. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397.
19. Li, M., D. Ren, M. Iseki, S. Takaki, and L. Rui. 2006. Differential role of SH2-B and APS in regulating energy and glucose homeostasis. Endocrinology 147:2163-2170.
20. Liu, B. P., and K. Burridge. 2000. Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not β1 integrins. Mol. Cell. Biol. 20:7160-7169.
21. Lucet, I. S., E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, and J. Rossjohn. 2006. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107:176-183.
22. Minami, A., M. Iseki, K. Kishi, M. Wang, M. Ogura, N. Furukawa, S. Hayashi, M. Yamada, T. Obata, Y. Takeshita, Y. Nakaya, Y. Bando, K. Izumi, S. A. Moodie, F. Kajiura, M. Matsumoto, K. Takatsu, S. Takaki, and Y. Ebina. 2003. Increased insulin sensitivity and hypoinsulinemia in APS knockout mice. Diabetes 52:2657-2665.
23. Moodie, S. A., J. Alleman-Sposeto, and T. A. Gustafson. 1999. Identification of the APS protein as a novel insulin receptor substrate. J. Biol. Chem. 274:11186-11193.
24. Nelms, K., T. J. O'Neill, S. Li, S. R. Hubbard, T. A. Gustafson, and W. E. Paul. 1999. Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain. Mamm. Genome 10:1160-1167.
25. Nishi, M., E. D. Werner, B. C. Oh, J. D. Frantz, S. Dhe-Paganon, L. Hansen, J. Lee, and S. E. Shoelson. 2005. Kinase activation through dimerization by human SH2-B. Mol. Cell. Biol. 25:2607-2621.
26. O'Brien, K. B., L. S. Argetsinger, M. Diakonova, and C. Carter-Su. 2003. YXXL motifs in SH2-Bβ are phosphorylated by JAK2, JAK1, and platelet-derived growth factor receptor and are required for membrane ruffling. J. Biol. Chem. 278:11970-11978.
27. O'Brien, K. B., J. J. O'Shea, and C. Carter-Su. 2002. SH2-B family members differentially regulate JAK family tyrosine kinases. J. Biol. Chem. 277:8673-8681.
28. Ohtsuka, S., S. Takaki, M. Iseki, K. Miyoshi, N. Nakagata, Y. Kataoka, N. Yoshida, K. Takatsu, and A. Yoshimura. 2002. SH2-B is required for both male and female reproduction. Mol. Cell. Biol. 22:3066-3077.
29. Osborne, M. A., S. Dalton, and J. P. Kochan. 1995. The yeast tribrid system-genetic detection of trans-phosphorylated ITAM-SH2-interactions. Bio/Technology 13:1474-1478.
30. O'Shea, J. J., M. Gadina, and R. D. Schreiber. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl.):S121-S131.
31. Peeters, P., S. D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, P. Philip, F. Monpoux, L. Van Rompaey, M. Baens, H. Van den Berghe, and P. Marynen. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia. Blood 90:2535-2540.
32. Qian, X., and D. D. Ginty. 2001. SH2-B and APS are multimeric adapters that augment TrkA signaling. Mol. Cell. Biol. 21:1613-1620.
33. Qian, X., A. Riccio, Y. Zhang, and D. D. Ginty. 1998. Identification and characterization of novel substrates of Trk receptors in developing neurons. Neuron 21:1017-1029.
34. Ren, D., M. Li, C. Duan, and L. Rui. 2005. Identification of SH2-B as a key regulator of leptin sensitivity, energy balance and body weight in mice. Cell Metab. 2:95-104. [Online.] doi:10.1016/j.cmet.2005.07.004.
35. Rui, L., and C. Carter-Su. 1999. Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc. Natl. Acad. Sci. USA 96:7172-7177.
36. Rui, L., D. R. Gunter, J. Herrington, and C. Carter-Su. 2000. Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-Bβ. Mol. Cell. Biol. 20:3168-3177.
37. Rui, L., L. S. Mathews, K. Hotta, T. A. Gustafson, and C. Carter-Su. 1997. Identification of SH2-Bβ as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol. Cell. Biol. 17:6633-6644.
38. c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266:1042-1045.
39. Saharinen, P., and O. Silvennoinen. 2002. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277:47954-47963.
40. Saharinen, P., K. Takaluoma, and O. Silvennoinen. 2000. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20:3387-3395.
41. Saharinen, P., M. Vihinen, and O. Silvennoinen. 2003. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14:1448-1459.
42. Silvennoinen, O., B. Witthuhn, F. W. Quelle, J. L. Cleveland, T. Yi, and J. N. Ihle. 1993. Structure of the murine JAK2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA 90:8429-8433.
43. Starr, R., T. A. Willson, E. M. Viney, L. J. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921.
44. Tong, W., J. Zhang, and H. F. Lodish. 2005. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105:4604-4612.
45. Uhlik, M. T., B. Temple, S. Bencharit, A. J. Kimple, D. P. Siderovski, and G. L. Johnson. 2005. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J. Mol. Biol. 345:1-20.
46. Wakioka, T., A. Sasaki, K. Mitsui, M. Yokouchi, A. Inoue, S. Komiya, and A. Yoshimura. 1999. APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 13:760-767.
47. Wilks, A. F., A. G. Harpur, R. R. Kurban, S. J. Ralph, G. Zurcher, and A. Ziemiecki. 1991. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11:2057-2065.
48. Yamaoka, K., P. Saharinen, M. Pesu, V. E. Holt III, O. Silvennoinen, and J. J. O'Shea. 2004. The Janus kinases (Jaks). Genome Biol. 5:253-256.
49. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, and A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-1320.
50. Yokouchi, M., R. Suzuki, M. Masuhara, S. Komiya, A. Inoue, and A. Yoshimura. 1997. Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation. Oncogene 15:7-15.
51. Yousaf, N., Y. Deng, Y. Kang, and H. Riedel. 2001. Four PSM/SH2-B alternative splice variants and their differential roles in mitogenesis. J. Biol. Chem. 276:40940-40948.
52. Zhao, R., S. Xing, Z. Li, X. Fu, Q. Li, S. B. Krantz, and Z. J. Zhao. 2005. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280:22788-22792.
53. Zhou, Y. J., M. Chen, N. A. Cusack, L. H. Kimmel, K. S. Magnuson, J. G. Boyd, W. Lin, J. L. Roberts, A. Lengi, R. H. Buckley, R. L. Geahlen, F. Candotti, M. Gadina, P. S. Changelian, and J. J. O'Shea. 2001. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8:959-969.
54. Zhou, Y. J., E. P. Hanson, Y. Q. Chen, K. Magnuson, M. Chen, P. G. Swann, R. L. Wange, P. S. Changelian, and J. J. O'Shea. 1997. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94:13850-13855.